Dipexium Pharmaceuticals CEO Natasha Giordano's 2021 pay jumps 32% to $3.2M
Dipexium Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: September 29, 2022
Dipexium Pharmaceuticals reported fiscal year 2021 executive compensation information on September 29, 2022.
In 2021, three executives at Dipexium Pharmaceuticals received on average a compensation package of $1.8M, a 9% increase compared to previous year.
Average pay of disclosed executives at Dipexium Pharmaceuticals
Natasha Giordano, Chief Executive Officer, received $3.2M in total, which increased by 32% compared to 2020. 72% of Giordano's compensation, or $2.3M, was in option awards. Giordano also received $306K in non-equity incentive plan, $557K in salary, as well as $22K in other compensation.
Rita M. O'Connor, Chief Financial Officer, received a compensation package of $1.8M, which increased by 28% compared to previous year. 65% of the compensation package, or $1.2M, was in option awards.
Michael J. Valentino, Chairman, earned $394K in 2021, a 64% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on September 29, 2022.